Stamm Bettina, Blaschke Martina, Wilken Lara, Wilde Deborah, Heppner Christina, Leha Andreas, Herrmann-Lingen Christoph, Siggelkow Heide
Endokrinologikum Saarbruecken Saarbruecken Germany.
Clinic of Gastroenterology, Gastrointestinal Oncology and Endocrinology University Medical Center Goettingen Goettingen Germany.
JBMR Plus. 2022 Feb 1;6(2):e10586. doi: 10.1002/jbm4.10586. eCollection 2022 Feb.
Quality of life (QoL) is impaired in patients with chronic hypoparathyroidism (HypoPT). With a recently developed specific patient questionnaire, the 28-item Hypoparathyroid Patient Questionnaire (HPQ 28), we were able to demonstrate an effect of laboratory parameters on symptoms and complaints identified by scales and items of the HPQ 28. Here, we evaluated the effect of conventional treatment modalities on QoL using this specific questionnaire. In this cross-sectional study, we included 49 HypoPT (41 female and 8 male) patients. Laboratory values of total serum calcium, magnesium, phosphate, calcium-phosphate product (CPP), and 24-hour urine for calcium and phosphate were analyzed. Patients completed the HPQ 28 questionnaire during the corresponding visit. Mean age was 57.3 ± 10.5 years and duration of disease 12.6 ± 9.8 years. Most patients (86%, = 42) were treated with the active vitamin D analogs calcitriol, alfacalcidol, or dihydrotachysterol (DHT). The use of calcium and magnesium supplements influenced scales on HPQ 28 in a dose-dependent manner. We detected a dose-dependent increase on the HPQ 28 scales "depression and anxiety" and "pain and cramps," and the item "numbness and tingling" related to calcitriol. This effect was independent of gender, age, underlying disease, kind of surgery, serum 25-hydroxyvitamin D, calcium, or phosphate values. This study presents the first data on specific symptoms of HypoPT patients dependent on different treatment modalities. Our data suggest that in part the reduced QoL in these patients might be caused by conventional treatment. © 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
慢性甲状旁腺功能减退症（HypoPT）患者的生活质量（QoL）受损。通过最近开发的一份特定患者问卷——28项甲状旁腺功能减退症患者问卷（HPQ 28），我们能够证明实验室参数对HPQ 28量表和项目所确定的症状及不适的影响。在此，我们使用这份特定问卷评估了传统治疗方式对生活质量的影响。在这项横断面研究中，我们纳入了49例甲状旁腺功能减退症患者（41例女性和8例男性）。分析了血清总钙、镁、磷、钙磷乘积（CPP）以及24小时尿钙和尿磷的实验室值。患者在相应就诊期间完成了HPQ 28问卷。平均年龄为57.3±10.5岁，病程为12.6±9.8年。大多数患者（86%，n = 42）接受活性维生素D类似物骨化三醇、阿法骨化醇或双氢速甾醇（DHT）治疗。钙和镁补充剂的使用以剂量依赖的方式影响HPQ 28量表。我们检测到HPQ 28量表“抑郁和焦虑”以及“疼痛和痉挛”以及与骨化三醇相关的项目“麻木和刺痛”呈剂量依赖性增加。这种效应与性别、年龄、基础疾病、手术类型、血清25 - 羟基维生素D、钙或磷值无关。本研究提供了关于依赖不同治疗方式的甲状旁腺功能减退症患者特定症状的首批数据。我们的数据表明，这些患者生活质量下降部分可能是由传统治疗引起的。© 2022作者。由Wiley Periodicals LLC代表美国骨与矿物质研究学会出版。
